Partnerships and Support
Amgen is committed to fully complying with the disclosure requirements of the European Federation of Pharmaceutical Industries and Associations (EFPIA) codes of practice.
The methodology Amgen used for the collection and organization of transfers of value to healthcare professionals and healthcare organizations can be found below.Methodological Note - Last Updated June 7, 2023
Transfers of Value (ToV) To Healthcare Organizations (HCOs)
DonationsWe will disclose Donations and Grants we provide to HCOs that support science, technology, medicine, healthcare, research or education.
Contribution to the costs related to scientific and/or educational eventsWe will disclose contributions towards the costs of events (fees, related expenses and sponsorships) provided by HCOs for healthcare professional education.
Fees for Service and ConsultancyWe will disclose fees and related expenses for travel and accommodation when Amgen contracts a HCO who provides consultancy services.
Transfers of Value (ToV) to Healthcare Professionals (HCPs)
Fees for Service and ConsultancyWe will disclose fees and related expenses for travel and accommodation when Amgen contracts a HCP who speaks on our behalf or provides consultancy services.
Contribution to the costs related to scientific and/or educational eventsWe will disclose registration fees, travel and accommodation when Amgen sponsor (fund) individual HCPs to attend scientific and/or educational events.
Research and Development Transfers of Value (ToV)
We will make aggregate disclosure of ToV associated with the planning and conduct of i) non-clinical studies, ii) clinical trials and iii) prospective non-interventional studies.
Patient Group Funding Disclosures
Amgen are committed to supporting meaningful exchange for the benefit of patients. We will disclose details of the support we provide to, and contracted services we receive from, Patient Groups. Reports on funding can be found here.
Amgen European Gateway and Reports on Transfers of Value to Members of the Healthcare Community
As an EFPIA member company, Amgen publishes the transfer of value reports in each country where we operate, on the respective Amgen website, or where required on national platforms by individual country industry associations. This gateway provides a link to the respective country reports.
Transfers of Value Report Links
In countries where Amgen doesn't have an affiliate or website, we have published the reports below.
Amgen completed the acquisition of Horizon Therapeutics Plc on October 6, 2023. Previously published Horizon Therapeutics Plc Transfers of Value Reports can be found below.
If you have any general queries on Amgen's EFPIA Disclosure Program, contact email@example.com.